Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Seeks Licensing Partner, Heart Failure Indication For Nebivolol

This article was originally published in The Pink Sheet Daily

Executive Summary

The company hopes to announce a partner for nebivolol this fall, roughly the same timeframe targeted for discussions with FDA on data needed for a congestive heart failure claim. The beta blocker is “approvable” at FDA for hypertension; Mylan expects to respond to the agency by year-end.

You may also be interested in...



Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement

Forest will assume development, sales and marketing rights for Mylan's beta blocker.

Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement

Forest will assume development, sales and marketing rights for Mylan's beta blocker.

Mylan's Nebivolol Is "Approvable" At FDA

The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel